Key result
Operator experience fails to reduce 30-day or 2-year major adverse events after PCI.
Why the study?
Operator experience influences outcomes after PCI, but its association within the controlled setting of a randomized clinical trial is unclear.
Does operator experience affect clinical outcomes in patients undergoing percutaneous coronary intervention randomized to different stent types and dual antiplatelet therapy durations?
RCT (n=2,003)
randomized
Yes
Does operator experience affect clinical outcomes in patients undergoing percutaneous coronary intervention randomized to different stent types and dual antiplatelet therapy durations?
Operator experience did not significantly affect the comparative efficacy and safety profile of randomized stent types or DAPT duration regimens in a controlled trial setting.
Answers are grounded in this paper and cite their sources.
Supports equivalent PCI outcomes across experience levels; hypothesis-generating and should not yet change practice.
Background Operator experience influences outcomes after percutaneous coronary intervention, but this association in the controlled setting of a randomized, clinical trial is unclear. Methods and Results We investigated operator‐related outcomes (30‐day and 2‐year efficacy and safety end points) among patients undergoing percutaneous coronary intervention and randomized to different dual antiplatelet therapy durations and stent types. A total of 2003 patients were analyzed, and 7 operator groups were compared. The majority of preprocedural and postprocedural characteristics were imbalanced. The primary end point of the study, the composite of death, myocardial infarction, or cerebrovascular accidents, did not differ among operators at 30 days or 2 years. There were no significant differences also for all other individual and composite end points analyzed at 30 days and 2 years, except for 2‐year stent thrombosis ( P =0.048) and bleeding events ( P =0.022 for Bleeding Academic Research Consortium type 2, 3, or 5). Adjusted comparisons for the main end points showed slight differences among operators at 30 days, but not at 2 years. There was no interaction of operator with dual antiplatelet therapy duration ( P =0.112) or stent type ( P =0.300). Results remained entirely consistent when operators were stratified by their experience. Conclusions There was a weak signal of heterogeneity across study operators for the 30‐day, but not the 2‐year, main study outcomes. No clear effect of operator or operator experience was observed for the comparative efficacy and safety profile of the randomized stent types or dual antiplatelet therapy duration regimens. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00611286.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2017) conducted an RCT in percutaneous coronary intervention (n=2,003). Operator experience vs. Different operator groups was evaluated on composite of death, myocardial infarction, or cerebrovascular accidents. Operator experience did not significantly affect the 30-day or 2-year primary composite endpoint of death, myocardial infarction, or cerebrovascular accidents in patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: